Seeking Alpha

Acorda Therapeutics (ACOR), a developer of drugs for treating neurological disorders, gains...

Acorda Therapeutics (ACOR), a developer of drugs for treating neurological disorders, gains 14.6% after reporting Q3 revenue of $93M and EPS of $0.40; while the latter missed by $0.33, the former beat by $2.2M, and investors appear reassured by positive comments regarding market acceptance of the company's Ampyra MS drug, made in partnership with ELN.

Check out Seeking Alpha’s new Earnings Center »

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs